$HITC
Healthcare Integrated Technologies Inc.

2024 Q4 Form 10-Q Financial Statement

#000149315224049910 Filed on December 13, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2023 Q4
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $343.8K $138.0K
YoY Change 149.09% -40.89%
% of Gross Profit
Research & Development $3.900K
YoY Change
% of Gross Profit
Depreciation & Amortization $55.70K
YoY Change
% of Gross Profit
Operating Expenses $670.2K $215.7K
YoY Change 210.77% -7.63%
Operating Profit -$670.2K -$215.7K
YoY Change 210.77% -7.63%
Interest Expense $12.84K
YoY Change -88.62%
% of Operating Profit
Other Income/Expense, Net -$13.94K -$12.84K
YoY Change 8.51% -96.86%
Pretax Income -$228.5K
YoY Change -64.46%
Income Tax
% Of Pretax Income
Net Earnings -$684.1K -$228.5K
YoY Change 199.4% -64.46%
Net Earnings / Revenue
Basic Earnings Per Share -$0.01
Diluted Earnings Per Share -$0.01
COMMON SHARES
Basic Shares Outstanding 102.2M shares 69.30M shares
Diluted Shares Outstanding 83.44M shares 68.19M shares

Balance Sheet

Concept 2024 Q4 2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $130.00
YoY Change 550.0%
Cash & Equivalents $2.014M $131.00
Short-Term Investments
Other Short-Term Assets $39.44K
YoY Change 11.6%
Inventory
Prepaid Expenses $33.02K $39.44K
Receivables
Other Receivables
Total Short-Term Assets $2.267M $39.57K
YoY Change 5628.58% 11.91%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles $436.7K $813.7K
YoY Change -46.33% 10.37%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $436.7K $813.7K
YoY Change -46.33% 10.37%
TOTAL ASSETS
Total Short-Term Assets $2.267M $39.57K
Total Long-Term Assets $436.7K $813.7K
Total Assets $2.703M $853.3K
YoY Change 216.82% 10.44%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $572.2K
YoY Change 288.71%
Accrued Expenses $546.4K
YoY Change 20.24%
Deferred Revenue $10.06K
YoY Change
Short-Term Debt $372.1K
YoY Change 14.48%
Long-Term Debt Due $225.0K
YoY Change -74.37%
Total Short-Term Liabilities $1.726M
YoY Change -54.01%
LONG-TERM LIABILITIES
Long-Term Debt $225.0K $225.0K
YoY Change 0.0%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $225.0K $225.0K
YoY Change 0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.726M
Total Long-Term Liabilities $225.0K $225.0K
Total Liabilities $944.2K $1.726M
YoY Change -45.29% -54.01%
SHAREHOLDERS EQUITY
Retained Earnings -$17.00M -$15.84M
YoY Change 7.31% 5.94%
Common Stock $18.54M $14.97M
YoY Change 23.85% 25.02%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.759M -$872.4K
YoY Change
Total Liabilities & Shareholders Equity $2.703M $853.3K
YoY Change 216.82% 10.44%

Cashflow Statement

Concept 2024 Q4 2023 Q4
OPERATING ACTIVITIES
Net Income -$684.1K -$228.5K
YoY Change 199.4% -64.46%
Depreciation, Depletion And Amortization $55.70K
YoY Change
Cash From Operating Activities -$378.7K -$3.049K
YoY Change 12319.38% -82.52%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $2.217M $2.769K
YoY Change 79956.59% -86.22%
NET CHANGE
Cash From Operating Activities -$378.7K -$3.049K
Cash From Investing Activities
Cash From Financing Activities $2.217M $2.769K
Net Change In Cash $1.838M -$280.00
YoY Change -656564.29% -72.87%
FREE CASH FLOW
Cash From Operating Activities -$378.7K -$3.049K
Capital Expenditures $0.00
Free Cash Flow -$3.049K
YoY Change -77.82%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q4 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q4 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--07-31
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
114214936 shares
CY2024Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2013662 usd
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
175562 usd
CY2024Q4 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
343787 usd
CY2023Q4 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
138017 usd
CY2023Q4 us-gaap Share Based Compensation
ShareBasedCompensation
21942 usd
CY2024Q4 dei Entity Registrant Name
EntityRegistrantName
Healthcare Integrated Technologies, Inc.
CY2024Q4 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2025
CY2024Q4 dei Entity Central Index Key
EntityCentralIndexKey
0001584693
CY2024Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
usd
CY2024Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
usd
CY2024Q3 us-gaap Deposits
Deposits
usd
CY2023Q4 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
usd
CY2023Q4 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
usd
CY2023Q4 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
usd
CY2024Q4 HITC Cash Received From Deferred Revenue
CashReceivedFromDeferredRevenue
usd
CY2023Q4 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
usd
CY2024Q4 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
usd
CY2023Q4 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
usd
CY2024Q4 us-gaap Interest Paid Net
InterestPaidNet
usd
CY2023Q4 us-gaap Interest Paid Net
InterestPaidNet
usd
CY2023Q4 HITC Shares Issued For Payment Of Accrued Expenses
SharesIssuedForPaymentOfAccruedExpenses
usd
CY2023Q4 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
usd
CY2024Q3 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
usd
CY2024 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
shares
CY2024Q4 dei Document Type
DocumentType
10-Q
CY2024Q4 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q4 dei Document Period End Date
DocumentPeriodEndDate
2024-10-31
CY2024Q4 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q4 dei Entity File Number
EntityFileNumber
001-36564
CY2024Q4 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2024Q4 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-1173741
CY2024Q4 dei Entity Address Address Line1
EntityAddressAddressLine1
311 S. Weisgarber Road
CY2024Q4 dei Entity Address City Or Town
EntityAddressCityOrTown
Knoxville
CY2024Q4 dei Entity Address State Or Province
EntityAddressStateOrProvince
TN
CY2024Q4 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
37919
CY2024Q4 dei City Area Code
CityAreaCode
(865)
CY2024Q4 dei Local Phone Number
LocalPhoneNumber
237-4448
CY2024Q4 dei Security12g Title
Security12gTitle
Common Stock, $0.001 par value
CY2024Q4 dei Entity Listing Par Value Per Share
EntityListingParValuePerShare
0.001
CY2024Q4 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q4 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q4 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q4 dei Entity Small Business
EntitySmallBusiness
false
CY2024Q4 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2024Q4 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2024Q4 dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
220000 usd
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
14000 usd
CY2024Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
33022 usd
CY2024Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
33022 usd
CY2024Q4 us-gaap Assets Current
AssetsCurrent
2266684 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
222584 usd
CY2024Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
436711 usd
CY2024Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
506743 usd
CY2024Q4 us-gaap Assets
Assets
2703395 usd
CY2024Q3 us-gaap Assets
Assets
729327 usd
CY2024Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
41448 usd
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
16637 usd
CY2024Q4 us-gaap Liabilities
Liabilities
944223 usd
CY2024Q3 us-gaap Liabilities
Liabilities
1022522 usd
CY2024Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2024Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
105204936 shares
CY2024Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
105204936 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
79853696 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
79853696 shares
CY2024Q4 us-gaap Common Stock Value
CommonStockValue
105205 usd
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
79854 usd
CY2024Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
18432757 usd
CY2024Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
15941603 usd
CY2024Q4 us-gaap Deposits
Deposits
220000 usd
CY2024Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-16998790 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-16314652 usd
CY2024Q4 us-gaap Stockholders Equity
StockholdersEquity
1759172 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-293195 usd
CY2024Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2703395 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
729327 usd
CY2024Q4 us-gaap Share Based Compensation
ShareBasedCompensation
256382 usd
CY2024Q4 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
54354 usd
CY2023Q4 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
55697 usd
CY2024Q4 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
15678 usd
CY2024Q4 us-gaap Operating Expenses
OperatingExpenses
670201 usd
CY2023Q4 us-gaap Operating Expenses
OperatingExpenses
215656 usd
CY2024Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-670201 usd
CY2023Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-215656 usd
CY2024Q4 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
13937 usd
CY2023Q4 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
12844 usd
CY2024Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-13937 usd
CY2023Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-12844 usd
CY2024Q4 us-gaap Net Income Loss
NetIncomeLoss
-684138 usd
CY2023Q4 us-gaap Net Income Loss
NetIncomeLoss
-228500 usd
CY2024Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2024Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2023Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2023Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2024Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
83435756 shares
CY2024Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
83435756 shares
CY2023Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
68189433 shares
CY2023Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
68189433 shares
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-293195 usd
CY2024Q4 us-gaap Net Income Loss
NetIncomeLoss
-684138 usd
CY2024Q4 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2232000 usd
CY2024Q4 HITC Receipt Of Cash Deposits On Stock Subscription Agreements
ReceiptOfCashDepositsOnStockSubscriptionAgreements
220000 usd
CY2024Q4 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
256381 usd
CY2024Q4 HITC Stock Issued During Period Value New Issuance Of Shares Payment Of Accrued Expenses
StockIssuedDuringPeriodValueNewIssuanceOfSharesPaymentOfAccruedExpenses
28124 usd
CY2024Q4 us-gaap Stockholders Equity
StockholdersEquity
1759172 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-665868 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-665868 usd
CY2023Q4 us-gaap Net Income Loss
NetIncomeLoss
-228500 usd
CY2023Q4 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
21942 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-872426 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-872426 usd
CY2024Q4 us-gaap Net Income Loss
NetIncomeLoss
-684138 usd
CY2023Q4 us-gaap Net Income Loss
NetIncomeLoss
-228500 usd
CY2024Q4 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
54354 usd
CY2023Q4 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
55697 usd
CY2024Q4 us-gaap Share Based Compensation
ShareBasedCompensation
256382 usd
CY2023Q4 us-gaap Share Based Compensation
ShareBasedCompensation
21942 usd
CY2024Q4 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
15678 usd
CY2023Q4 HITC Cash Received From Deferred Revenue
CashReceivedFromDeferredRevenue
10061 usd
CY2024Q4 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-14000 usd
CY2023Q4 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
5345 usd
CY2024Q4 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-14179 usd
CY2023Q4 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
46931 usd
CY2024Q4 HITC Accounts Payable And Accrued Expenses Related Party
AccountsPayableAndAccruedExpensesRelatedParty
-45575 usd
CY2023Q4 HITC Accounts Payable And Accrued Expenses Related Party
AccountsPayableAndAccruedExpensesRelatedParty
34802 usd
CY2024Q4 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
24811 usd
CY2023Q4 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
61363 usd
CY2024Q4 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-378667 usd
CY2023Q4 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3049 usd
CY2024Q4 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2232000 usd
CY2024Q4 HITC Cash Deposits On Common Stock Subscription Agreements
CashDepositsOnCommonStockSubscriptionAgreements
220000 usd
CY2024Q4 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
35172 usd
CY2023Q4 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
12769 usd
CY2024Q4 HITC Repayments Of Restricted Cash
RepaymentsOfRestrictedCash
220000 usd
CY2024Q4 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
50405 usd
CY2023Q4 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
10000 usd
CY2024Q4 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2216767 usd
CY2023Q4 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2769 usd
CY2024Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1838100 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-280 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
175562 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
411 usd
CY2024Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2013662 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
131 usd
CY2024Q4 HITC Shares Issued For Payment Of Accrued Expenses
SharesIssuedForPaymentOfAccruedExpenses
28124 usd
CY2024Q4 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_843_eus-gaap--UseOfEstimates_zgQ7JwENNDSi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_zmO3uUxgPFmf">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates. We base our estimates on experience and various other assumptions that are believed to be reasonable under the circumstances. We evaluate our estimates and assumptions on a regular basis and actual results may differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q4 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p id="xdx_84F_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zPrffTeKCWB2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_zK0CfRP1LGYk">Reclassifications</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain prior period amounts may be reclassified to conform to current period presentation with no changes to previously reported net loss or stockholders’ deficit.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q4 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
2200000 shares
CY2024Q4 us-gaap Share Price
SharePrice
0.10
CY2024Q4 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_849_eus-gaap--ConcentrationRiskCreditRisk_zVx7YSkc9yP" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_z8uzNZZBkOc9">Concentration of Credit Risk</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially expose the Company to credit risk consist of demand deposits with a financial institution. The Company is exposed to credit risk on its cash and cash equivalents in the event of default by the financial institution to the extent account balances exceed the amount insured by the FDIC, which is $<span id="xdx_90C_eus-gaap--CashFDICInsuredAmount_iI_c20241031_zwDxo5CyrK3h" title="Cash FDIC insured amount">250,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q4 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000 usd
CY2024Q4 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
15678 usd
CY2024Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
436711 usd
CY2024Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
506743 usd
CY2024Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
0 usd
CY2024Q3 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
0 usd
CY2024Q4 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
17685 usd
CY2023Q4 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
2668 usd
CY2024Q4 us-gaap Net Income Loss
NetIncomeLoss
-684138 usd
CY2024 us-gaap Net Income Loss
NetIncomeLoss
-702486 usd
CY2024Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
763761 usd
CY2024Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
-286515 usd
CY2024Q4 HITC Finite Lived Intangible Assets Reserve For Impairment
FiniteLivedIntangibleAssetsReserveForImpairment
-40535 usd
CY2024Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
436711 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
801636 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
-237044 usd
CY2024Q3 HITC Finite Lived Intangible Assets Reserve For Impairment
FiniteLivedIntangibleAssetsReserveForImpairment
-57849 usd
CY2024Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
506743 usd
CY2024Q4 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
54354 usd
CY2023Q4 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
55697 usd
CY2024Q4 us-gaap Acquired Finite Lived Intangible Assets Weighted Average Useful Life
AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
P5Y
CY2024Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
161642 usd
CY2024Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
212335 usd
CY2024Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
3188 usd
CY2024Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
3188 usd
CY2024Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
3188 usd
CY2024Q4 HITC Finite Lived Intangible Assets Amortization Expense After Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour
53170 usd
CY2024Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
436711 usd
CY2024Q4 us-gaap Accounts Payable And Accrued Liabilities Current And Noncurrent
AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
267568 usd
CY2024Q3 us-gaap Accounts Payable And Accrued Liabilities Current And Noncurrent
AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
370678 usd
CY2024Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
17224 usd
CY2024Q4 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
24224 usd
CY2024Q3 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
16637 usd
CY2024Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
41448 usd
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
16637 usd
CY2024Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
225000 usd
CY2024Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
225000 usd
CY2024Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
105204936 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
79853696 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
4000000 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
2282031 shares
CY2024Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
5000000 shares
CY2024 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
3100000 shares
CY2024Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
200000 shares
CY2024Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
1750000 shares
CY2024 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
1382031 shares
CY2024Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
7050000 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
4000000 shares
CY2024Q4 us-gaap Payments For Rent
PaymentsForRent
10119 usd
CY2023Q3 us-gaap Payments For Legal Settlements
PaymentsForLegalSettlements
4705900 usd
CY2024Q2 us-gaap Payments For Legal Settlements
PaymentsForLegalSettlements
4705900 usd

Files In Submission

Name View Source Status
0001493152-24-049910-index-headers.html Edgar Link pending
0001493152-24-049910-index.html Edgar Link pending
0001493152-24-049910.txt Edgar Link pending
0001493152-24-049910-xbrl.zip Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
form10-q_001.jpg Edgar Link pending
hitc-20241031.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
hitc-20241031_cal.xml Edgar Link unprocessable
hitc-20241031_def.xml Edgar Link unprocessable
hitc-20241031_lab.xml Edgar Link unprocessable
hitc-20241031_pre.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending